Rice Hall James & Associates LLC increased its position in shares of Haemonetics Corp. (NYSE:HAE) by 1.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 116,121 shares of the company’s stock after buying an additional 1,645 shares during the period. Rice Hall James & Associates LLC’s holdings in Haemonetics Corp. were worth $3,366,000 as of its most recent filing with the SEC.
Several other hedge funds also recently added to or reduced their stakes in HAE. Ngam Advisors L.P. bought a new stake in Haemonetics Corp. during the first quarter worth about $362,000. TIAA CREF Investment Management LLC raised its stake in Haemonetics Corp. by 20.6% in the first quarter. TIAA CREF Investment Management LLC now owns 234,813 shares of the company’s stock worth $8,214,000 after buying an additional 40,032 shares during the last quarter. Teachers Advisors Inc. raised its stake in Haemonetics Corp. by 4.0% in the first quarter. Teachers Advisors Inc. now owns 77,842 shares of the company’s stock worth $2,723,000 after buying an additional 2,968 shares during the last quarter. Prudential Financial Inc. raised its stake in Haemonetics Corp. by 5.4% in the first quarter. Prudential Financial Inc. now owns 124,632 shares of the company’s stock worth $4,360,000 after buying an additional 6,400 shares during the last quarter. Finally, BlackRock Inc. raised its stake in Haemonetics Corp. by 125.7% in the first quarter. BlackRock Inc. now owns 3,501 shares of the company’s stock worth $122,000 after buying an additional 1,950 shares during the last quarter. Institutional investors own 98.64% of the company’s stock.
Haemonetics Corp. (NYSE:HAE) traded up 0.44% during trading on Thursday, hitting $36.45. The stock had a trading volume of 229,476 shares. The firm’s market cap is $1.87 billion. The company has a 50-day moving average of $36.72 and a 200 day moving average of $32.47. Haemonetics Corp. has a 52-week low of $25.98 and a 52-week high of $38.06.
Haemonetics Corp. (NYSE:HAE) last posted its quarterly earnings results on Monday, August 1st. The company reported $0.25 EPS for the quarter, missing the Zacks’ consensus estimate of $0.28 by $0.03. The business had revenue of $210 million for the quarter, compared to the consensus estimate of $205.41 million. Haemonetics Corp. had a negative net margin of 7.25% and a positive return on equity of 10.75%. Haemonetics Corp.’s revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.35 earnings per share. On average, equities research analysts predict that Haemonetics Corp. will post $1.44 earnings per share for the current fiscal year.
A number of analysts recently issued reports on HAE shares. Zacks Investment Research upgraded Haemonetics Corp. from a “strong sell” rating to a “hold” rating in a research note on Monday, July 4th. Benchmark Co. boosted their price objective on Haemonetics Corp. from $28.00 to $32.00 and gave the company a “hold” rating in a research note on Tuesday, August 2nd. Jefferies Group boosted their price objective on Haemonetics Corp. from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Barrington Research cut Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 3rd. Finally, Sidoti cut Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a research report on Monday, August 15th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. Haemonetics Corp. currently has a consensus rating of “Hold” and a consensus price target of $34.50.
In other news, CEO Christopher Simon bought 60,000 shares of Haemonetics Corp. stock in a transaction dated Thursday, August 4th. The shares were purchased at an average cost of $35.00 per share, with a total value of $2,100,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronald Merriman sold 4,337 shares of Haemonetics Corp. stock in a transaction dated Wednesday, August 17th. The stock was sold at an average price of $35.14, for a total value of $152,402.18. Following the completion of the sale, the director now directly owns 22,088 shares in the company, valued at $776,172.32. The disclosure for this sale can be found here. 1.50% of the stock is owned by insiders.
About Haemonetics Corp.
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corp. (NYSE:HAE).
Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.